[Monoclonal antibodies: technology around the clock for new therapeutic hopes].
Département Recherche, Laboratoire Français du Fractionnement et des Biotechnologies, 3, av. des Tropiques, BP 305, Les Ulis, 91958 Courtaboeuf, France.
- Published Article
Comptes Rendus Biologies
- Publication Date
Apr 01, 2006
Engineering monoclonal antibodies, now widely used in the clinic, has made it possible to develop a new generation of antibodies with optimized functional properties. These antibodies should allow a significant improvement of the treatment of diseases where only few drugs are available, if any. However, the cost of treatments with monoclonal antibodies requires further improvements in production and purification technologies, and raises the question of generic antibodies. The present review summarizes some of the technological past and present challenges in the field.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 04/09/2020 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/16644492